<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="with an excellent safety profile since revolutionized the management of" exact="hepatitis" post="c virus (HCV) patients. Published papers have suggested a"/>
 <result pre="patients. Published papers have suggested a possible increased incidence of" exact="hepatocellular carcinoma" post="(HCC) after successful DAAs treatment. Other papers have been"/>
 <result pre="the de novo occurrence of HCC in patients with liver" exact="cirrhosis" post="(LC). Patients and Methods A prospective cohort study has"/>
 <result pre="with the HCV get chronic hepatitis, which may progress to" exact="cirrhosis" post="in 20% of patients within 2–3 decades; a quarter"/>
 <result pre="a quarter of these patients will develop complications, such as" exact="hepatocellular carcinoma" post="(HCC), portal hypertension, and liver decompensation, with an average"/>
 <result pre="these patients will develop complications, such as hepatocellular carcinoma (HCC)," exact="portal hypertension," post="and liver decompensation, with an average 5-year survival rate"/>
 <result pre="50%.3 Hepatocellular carcinoma is the fifth most frequent form of" exact="cancer" post="worldwide, and it holds the second cause of malignancy-related"/>
 <result pre="most parts of the world (about 2–3% per year). Liver" exact="cirrhosis" post="(LC) is the major risk factor or HCC in"/>
 <result pre="management of HCV patients.7 Interferon era teaches us that after" exact="cirrhosis" post="has been established, eradication of HCV infection is not"/>
 <result pre="the de novo occurrence of HCC in patients with liver" exact="cirrhosis" post="who are treated by DAAs. Materials and Methods Study"/>
 <result pre="from March 2016 till March 2019 in Assiut center for" exact="viral hepatitis" post="mangment (one of the national established centers in every"/>
 <result pre="March 2016 till March 2019 in Assiut center for viral" exact="hepatitis" post="mangment (one of the national established centers in every"/>
 <result pre="and Alrajhi University Hospital for Liver on 350 HCV-related liver" exact="cirrhosis" post="patients who are seeking for HCV treatment by direct-acting"/>
 <result pre="from every included patient. Patients with HBV co-infection, renal impairment," exact="hepatocellular carcinoma" post="have been excluded from the study. A complete history"/>
 <result pre="have analyzed data from 350 consecutive patients with HCV-related liver" exact="cirrhosis" post="who have been treated with direct-acting antivirals between March"/>
 <result pre="55.4% of patients were males. As high as 30.3% had" exact="diabetes mellitus" post="(D.M), and 84.3% of patients are naïve. PCR Median"/>
 <result pre="± 0.56 mg/dL. Ascites is in 12.3% of patients and" exact="hepatic encephalopathy" post="in 2.6% of patients. The baseline characteristics of the"/>
 <result pre="0.56 mg/dL. Ascites is in 12.3% of patients and hepatic" exact="encephalopathy" post="in 2.6% of patients. The baseline characteristics of the"/>
 <result pre="± 1.07 (3–6) PCR Median (range) 511,897 (52–815,000,000) Abbreviations: DM," exact="diabetes mellitus;" post="HTN, hypertension; S+R, sofosbuvir+ribavirin; S+S, sofosbuvir+Semiprevir; s+d±r, sofosbuvir+daclatasvir±ribavirin. Table"/>
 <result pre="27.0 (5.0–157.0) Note: *Significant. Abbreviations: SVR, sustained virological response; HE," exact="hepatic encephalopathy;" post="BIL, bilirubin; ALB, albumin; INR, international normalized ratio; AFP,"/>
 <result pre="4.8% 1.000 Note: *Significant. Abbreviations: SVR, sustained virological response; DM," exact="diabetes mellitus;" post="HTN, hypertension; HE, hepatic encephalopathy. Evolution of Liver Function"/>
 <result pre="SVR, sustained virological response; DM, diabetes mellitus; HTN, hypertension; HE," exact="hepatic encephalopathy." post="Evolution of Liver Function Significant improvement in liver enzymes"/>
 <result pre="16 (76.2%) Note: *Significant. Abbreviations: SVR, sustained virological response; HCC," exact="hepatocellular carcinoma." post="Table 5 Characteristics of HCC Patients with SVR and"/>
 <result pre="27 17 10 22 5 8 Abbreviations: No, number; HCC," exact="hepatocellular carcinoma;" post="SVR, sustained virological response; Non-SVR, non-sustained virological response; TTT,"/>
 <result pre="non-sustained virological response; TTT, treatment; m, month; AFP, alpha-fetoprotein; DM," exact="diabetes mellitus." post="Figure 1 Kaplan–Meier curve for HCC occurrence after treatment."/>
 <result pre="curve for HCC occurrence after treatment. Discussion The therapy of" exact="hepatitis" post="C has dramatically changed since 2013. Direct-acting antivirals against"/>
 <result pre="appears to be high in some real-world studies, regardless of" exact="cirrhosis" post="status.14 Resolution of HCV infection in these patients leads"/>
 <result pre="to evaluate the impact of DAAs on patients with liver" exact="cirrhosis" post="in our locality regarding the outcome and development of"/>
 <result pre="colleagues have reported that SVR is 95.2% in their liver" exact="cirrhosis" post="patients,21 Also the ALLY-1 trial looks at the effects"/>
 <result pre="Daclatasvir/Sofosbuvir with ribavirin on patients with advanced cirrhosis, including decompensated" exact="cirrhosis" post="across 5 of the 6 major HCV genotypes, only"/>
 <result pre="noted a high treatment response with Child-Pugh A or B" exact="cirrhosis" post="(93%); SVR is 100% in genotype 4 patients.22 In"/>
 <result pre="have shown an epidemiological association between HCV and type 2" exact="diabetes mellitus" post="(T2DM). The data from the National Health and Nutrition"/>
 <result pre="also have demonstrated that in patients with risk factors for" exact="metabolic syndrome," post="the presence of chronic HCV infection has increased the"/>
 <result pre="study of 564 noncirrhotic HCV‐infected patients and control‐matched with noncirrhotic" exact="hepatitis" post="B virus-infected patients has demonstrated an increased prevalence rate"/>
 <result pre="SVR have shown a significant reduction in the frequency of" exact="hepatic encephalopathy" post="episodes, improvement in the management of ascites. De-novo HCC"/>
 <result pre="have shown a significant reduction in the frequency of hepatic" exact="encephalopathy" post="episodes, improvement in the management of ascites. De-novo HCC"/>
 <result pre="patients who have achieved a SVR after IFN-free treatment with" exact="cirrhosis" post="with no history of liver cancer and they have"/>
 <result pre="SVR after IFN-free treatment with cirrhosis with no history of" exact="liver cancer" post="and they have found that HCC occurrence rate is"/>
 <result pre="after IFN-free treatment with cirrhosis with no history of liver" exact="cancer" post="and they have found that HCC occurrence rate is"/>
 <result pre="of data from a large prospective study of patients with" exact="hepatitis" post="C virus–associated compensated or decompensated cirrhosis, Calvaruso et al"/>
 <result pre="et al. The current and future disease burden of chronic" exact="hepatitis" post="C virus infection in Egypt. Arab J Gastroenterol. 2014;15(2):45–52."/>
 <result pre="doi:10.1016/j.ajg.2014.04.00325097045 3.PlanasR, BallestéB, AlvarezMA, et al. Natural history of decompensated" exact="hepatitis" post="C virus-related cirrhosis. A study of 200 patients. J"/>
 <result pre="Hepatol. 2004;40(5):823–830. doi:10.1016/j.jhep.2004.01.00515094231 4.JemalA, BrayF, CenterMM, FerlayJ, WardE, FormanD. Global" exact="cancer" post="statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855 5.RyersonAB, EhemanCR,"/>
 <result pre="the Status of Cancer, 1975–2012, featuring the increasing incidence of" exact="liver cancer." post="Cancer. 2016;122(9):1312–1337. doi:10.1002/cncr.2993626959385 6.MoriyaK, FujieH, ShintaniY, et al. The"/>
 <result pre="doi:10.1002/cncr.2993626959385 6.MoriyaK, FujieH, ShintaniY, et al. The core protein of" exact="hepatitis" post="C virus induces hepatocellular carcinoma in transgenic mice. Nat"/>
 <result pre="et al. The core protein of hepatitis C virus induces" exact="hepatocellular carcinoma" post="in transgenic mice. Nat Med. 1998;4(9):1065. doi:10.1038/20539734402 7.BurraP, GianniniEG,"/>
 <result pre="Liver Int. 2018;38(8):1338–1362. doi:10.1111/liv.1375529637743 8.BuonfiglioliF, BrillantiS. Direct antiviral therapy for" exact="hepatitis" post="C and hepatocellular carcinoma: facing the conundrum. Hepatoma Res."/>
 <result pre="9.SangiovanniA, PratiGM, FasaniP, et al. The natural history of compensated" exact="cirrhosis" post="due to hepatitis C virus: a 17-year cohort study"/>
 <result pre="et al. The natural history of compensated cirrhosis due to" exact="hepatitis" post="C virus: a 17-year cohort study of 214 patients."/>
 <result pre="Suarez-CuervoC, NelsonDR, FriedMW, SegalJB, SulkowskiMS. Oral direct-acting agent therapy for" exact="hepatitis" post="C virus infection: a systematic review. Ann Intern Med."/>
 <result pre="2017;166(9):637–648. doi:10.7326/M16-257528319996 12.ZanettoA, ShalabyS, FerrareseA, et al. Direct-acting antivirals and" exact="hepatocellular carcinoma" post="occurrence and recurrence in hepatitis C virus-related liver cirrhosis:"/>
 <result pre="al. Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in" exact="hepatitis" post="C virus-related liver cirrhosis: fact or fiction. Hepatoma Res."/>
 <result pre="13.MessinaJP, HumphreysI, FlaxmanA, et al. Global distribution and prevalence of" exact="hepatitis" post="C virus genotypes. Hepatology. 2015;61(1):77–87. doi:10.1002/hep.2725925069599 14.GayamV, KhalidM, MandalAK,"/>
 <result pre="doi:10.1002/hep.2725925069599 14.GayamV, KhalidM, MandalAK, et al. Direct-acting antivirals in chronic" exact="hepatitis" post="C genotype 4 infection in community care setting. Gastroenterol"/>
 <result pre="doi:10.14740/gr999w 15.KanwalF, KramerJ, AschSM, ChayanupatkulM, CaoY, El-SeragHB. Risk of hepatocellular" exact="cancer" post="in HCV patients treated with direct-acting antiviral agents. Gastroenterology."/>
 <result pre="doi:10.1053/j.gastro.2017.06.01228642197 16.LiDK, RenY, FiererDS, et al. The short-term incidence of" exact="hepatocellular carcinoma" post="is not increased after hepatitis C treatment with direct-acting"/>
 <result pre="The short-term incidence of hepatocellular carcinoma is not increased after" exact="hepatitis" post="C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology."/>
 <result pre="eradication induced by direct-acting antiviral agents reduces the risk of" exact="hepatocellular carcinoma." post="J Hepatol. 2017;pii: S0168–8278 (17)32273–0. 18.RinaldiL, Di FranciaR, CoppolaN,"/>
 <result pre="18.RinaldiL, Di FranciaR, CoppolaN, et al. Hepatocellular carcinoma in HCV" exact="cirrhosis" post="after viral clearance with direct acting antiviral therapy: preliminary"/>
 <result pre="19.ContiF, BuonfiglioliF, ScuteriA, et al. Early occurrence and recurrence of" exact="hepatocellular carcinoma" post="in HCV-related cirrhosis treated with direct acting antivirals. J"/>
 <result pre="al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related" exact="cirrhosis" post="treated with direct acting antivirals. J Hepatol. 2016;65:727–733. doi:10.1016/j.jhep.2016.06.01527349488"/>
 <result pre="doi:10.1016/j.jhep.2016.06.01527349488 20.KozbialK, MoserS, SchwarzerR, et al. Unexpected high incidence of" exact="hepatocellular carcinoma" post="in cirrhotic patients with sustained virologic response following interferon-free"/>
 <result pre="Hepatol. 2016;65(4):856–858. doi:10.1016/j.jhep.2016.06.00927318327 21.CalvarusoV, CabibboG, CacciolaI, et al. Incidence of" exact="hepatocellular carcinoma" post="in patients with HCV-associated cirrhosis treated with direct-acting antiviral"/>
 <result pre="et al. Incidence of hepatocellular carcinoma in patients with HCV-associated" exact="cirrhosis" post="treated with direct-acting antiviral agents. Gastroenterology. 2018;155(2):411–421. doi:10.1053/j.gastro.2018.04.00829655836 22.PoordadF,"/>
 <result pre="SchiffER, VierlingJM, et al. Daclatasvir with sofosbuvir and ribavirin for" exact="hepatitis" post="C virus infection with advanced cirrhosis or post-liver transplantation"/>
 <result pre="sofosbuvir and ribavirin for hepatitis C virus infection with advanced" exact="cirrhosis" post="or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–1505. doi:10.1002/hep.2844626754432 23.MehtaSH, BrancatiFL,"/>
 <result pre="doi:10.1002/hep.2844626754432 23.MehtaSH, BrancatiFL, SulkowskiMS, et al. Prevalence of type 2" exact="diabetes mellitus" post="among persons with hepatitis C virus infection in the"/>
 <result pre="al. Prevalence of type 2 diabetes mellitus among persons with" exact="hepatitis" post="C virus infection in the United States. Ann Intern"/>
 <result pre="Clinical outcomes of direct-acting antiviral therapy in patients with compensated" exact="hepatitis" post="C virus-related cirrhosis. Hepatoma Res. 2017;3(9):209–214. doi:10.20517/2394-5079.2017.28 27.RomanoA, AngeliP,"/>
 <result pre="Res. 2017;3(9):209–214. doi:10.20517/2394-5079.2017.28 27.RomanoA, AngeliP, PiovesanS, et al. Newly diagnosed" exact="hepatocellular carcinoma" post="in patients with advanced hepatitis C treated with DAAs:"/>
 <result pre="et al. Newly diagnosed hepatocellular carcinoma in patients with advanced" exact="hepatitis" post="C treated with DAAs: a prospective population study. J"/>
</results>
